CompletedPhase 2NCT02024555

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

Studying Sarcoidosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Vanderbilt University
Principal Investigator: Wonder Drake, MD
Vanderbilt University School of Medicine
Intervention: Levofloxacin(drug)
Enrollment: 97 target
Eligibility: 18 years · All sexes
Timeline: 2014 – 2019

Study locations (6)

Albany Medical Center, Albany, New York, United States
University of Cincinnati, Cincinnati, Ohio, United States
Cleveland Clinic, Cleveland, Ohio, United States
Ohio State University, Columbus, Ohio, United States
Medical University of South Carolina, Charleston, South Carolina, United States
Vanderbilt University School of Medicine, Nashville, Tennessee, United States

Collaborators

National Heart, Lung, and Blood Institute (NHLBI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02024555 on ClinicalTrials.gov

Other trials for Sarcoidosis

Additional recruiting or active studies for the same condition.

See all trials for Sarcoidosis →

← Back to all trials